NYSE · LLY
Eli Lilly and Company
$1,431.47+$57.77 (+4.21%)
Eli Lilly and Company’s quoted price is above the reported 52-week high. The range and quote may have different update times.
Loading market information…
NASDAQ · APMD · USD
Stock price, earnings
Quote as of Oct 30, 2026, 02:15 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Apnimed, Inc.’s quoted price sits in the lower half of its reported 52-week range, 52.42% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Apnimed, Inc.’s next earnings report is currently expected on Dec 8, 2026, with estimated earnings per share of -$0.64. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Apnimed, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Apnimed, Inc. operates as a clinical pharmaceutical company that develops and manufactures novel oral therapies that address the neurobiology of sleep-related breathing diseases in global markets. Its products include AD109, an oral therapy designed to treat obstructive sleep apnea (OSA) by targeting the underlying neuromuscular dysfunction. The company was incorporated in 2017 and is based in Cambridge, Massachusetts.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 02:16 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
THE ANALYST VIEW
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
Consensus coverage: 1 contributors · Median target $60.00.
Average targets in published notes for each window. These figures use a different sample from the consensus above.
KEEP COMPARING
$1,431.47+$57.77 (+4.21%)
Eli Lilly and Company’s quoted price is above the reported 52-week high. The range and quote may have different update times.
$277.79+$2.59 (+0.94%)
Johnson & Johnson’s quoted price sits in the upper half of its reported 52-week range, 1.17% below the high.
$295.06+$4.27 (+1.47%)
AbbVie Inc.’s quoted price is above the reported 52-week high. The range and quote may have different update times.
$149.34+$3.01 (+2.06%)
Merck & Co., Inc.’s quoted price sits in the upper half of its reported 52-week range, 4.83% below the high.
$409.10-$1.81 (-0.44%)
UnitedHealth Group Incorporated’s quoted price sits in the upper half of its reported 52-week range, 11.38% below the high.
$699.92-$9.26 (-1.31%)
Thermo Fisher Scientific Inc.’s quoted price sits in the upper half of its reported 52-week range, 1.68% below the high.
$70.10-$1.08 (-1.52%)
Inspire Medical Systems, Inc.’s quoted price sits in the lower half of its reported 52-week range, 52.32% below the high.
$0.87-$0.02 (-2.02%)
Nyxoah S.A.’s quoted price sits in the lower half of its reported 52-week range, 85.3% below the high.
